Katarina Ilic, MD MSc PhD MPH, currently a Senior Medical Director, Clinical Science, at Rare, Genetics and Hematology Therapeutic Area Unit (TAU) at Takeda, is a safety physician, pharmacologist/clinical pharmacologist and a pharmacoepidemiologist with extensive experience in clinical development, drug safety, clinical safety, and pharmacovigilance. Prior to joining Shire, which was acquired by Takeda, Katarina worked in Drug Safety as a Senior and an Executive Medical Director, Head of Drug Safety. As an active participant in the International Society of Pharmacovigilance (ISoP) for more than 10 years, Dr. Ilic was appointed the title of ISoP fellow (FISoP). Before working in the pharmaceutical industry, Katarina was a professor at the Department of Pharmacology at the School of Pharmacy, University of Belgrade and an expert appointed by the Ministry of Health of the Republic of Serbia. She published manuscripts in peer-reviewed journals and regularly serves as reviewer.
